TARGETED THERAPEUTIC MILD HYPERCAPNIA AFTER RESUSCITATED CARDIAC ARREST: A PHASE III MULTI-CENTRE RANDOMISED CONTROLLED TRIAL (THE TAME CARDIAC ARREST TRIAL)

Abstract

The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.